1. Lopez-Siles, M., et al., Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. Isme j, 2017. 11(4): p. 841-852.
2. Martín, R., et al., Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic. Front Microbiol, 2017. 8: p. 1226.
3. Martín, R., et al., Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol, 2015. 15: p. 67.
4. Rashed, R., R. Valcheva, and L.A. Dieleman, Manipulation of Gut Microbiota as a Key Target for Crohn's Disease. Front Med (Lausanne), 2022. 9: p. 887044.
5. Carlsson, A.H., et al., Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. Scand J Gastroenterol, 2013. 48(10): p. 1136-44.
6. Qiu, X., et al., Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis, 2013. 7(11): p. e558-68.
7. Sokol, H., et al., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A, 2008. 105(43): p. 16731-6.
8. Barkas, F., et al., Electrolyte and acid-base disorders in inflammatory bowel disease. Ann Gastroenterol, 2013. 26(1): p. 23-28.
9. Lapidus, A. and C. Einarsson, Bile composition in patients with ileal resection due to Crohn's disease. Inflamm Bowel Dis, 1998. 4(2): p. 89-94.
10. Roychowdhury, S., et al., Faecalibacterium prausnitzii and a Prebiotic Protect Intestinal Health in a Mouse Model of Antibiotic and Clostridium difficile Exposure. JPEN J Parenter Enteral Nutr, 2018. 42(7): p. 1156-1167.
11. Balsells, E., et al., Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health, 2019. 9(1): p. 010407.
12. Rohlke, F. and N. Stollman, Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol, 2012. 5(6): p. 403-20.
13. Hayashi, H., et al., Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostridium difficile toxin B. J Gen Physiol, 2004. 123(5): p. 491-504.
14. Hayashi, A., et al., The Butyrate-Producing Bacterium Clostridium butyricum Suppresses Clostridioides difficile Infection via Neutrophil- and Antimicrobial Cytokine-Dependent but GPR43/109a-Independent Mechanisms. J Immunol, 2021. 206(7): p. 1576-1585.
15. Packeiser, H., et al., An extremely simple and effective colony PCR procedure for bacteria, yeasts, and microalgae. Appl Biochem Biotechnol, 2013. 169(2): p. 695-700.
16. Ohura, K., et al., Establishment and Characterization of a Novel Caco-2 Subclone with a Similar Low Expression Level of Human Carboxylesterase 1 to Human Small Intestine. Drug Metab Dispos, 2016. 44(12): p. 1890-1898.
17. Wrzosek, L., et al., Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol, 2013. 11: p. 61.
18. Pineiro, M. and C. Stanton, Probiotic bacteria: legislative framework-- requirements to evidence basis. J Nutr, 2007. 137(3 Suppl 2): p. 850s-3s.
19. Duncan, S.H., et al., Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol, 2002. 52(Pt 6): p. 2141-2146.
20. Barcenilla, A., et al., Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol, 2000. 66(4): p. 1654-61.
21. Zhou, D., et al., Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol, 2017. 23(1): p. 60-75.
22. Li, G., et al., Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Gut Microbes, 2021. 13(1): p. 1968257.
23. Couto, M.R., et al., Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. Pharmacol Res, 2020. 159: p. 104947.
24. Breyner, N.M., et al., Microbial Anti-Inflammatory Molecule (MAM) from Faecalibacterium prausnitzii Shows a Protective Effect on DNBS and DSS-Induced Colitis Model in Mice through Inhibition of NF-κB Pathway. Front Microbiol, 2017. 8: p. 114.
25. Hu, W., et al., Biodiversity and Physiological Characteristics of Novel Faecalibacterium prausnitzii Strains Isolated from Human Feces. Microorganisms, 2022. 10(2).
26. Koziolek, M., et al., Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap(®) System. J Pharm Sci, 2015. 104(9): p. 2855-63.
27. Hourigan, S.K., et al., Fecal Transplant in Children With Clostridioides difficile Gives Sustained Reduction in Antimicrobial Resistance and Potential Pathogen Burden. Open Forum Infect Dis, 2019. 6(10): p. ofz379.
28. Xu, J., et al., Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes, 2020. 12(3): p. 224-236.
29. Vrieze, A., et al., Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology, 2012. 143(4): p. 913-6.e7.
30. Ueda, A., et al., Identification of Faecalibacterium prausnitzii strains for gut microbiome-based intervention in Alzheimer's-type dementia. Cell Rep Med, 2021. 2(9): p. 100398.